US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ホーム
投資
株式
アメリカ
NASDAQ
Atea Pharmaceuticals Inc (AVIR) 銘柄情報

Atea Pharmaceuticals Inc (AVIR)

4.99

0.08

(1.63%)

終了 7月11日 5:00AM

4.6503

-0.3397

(-6.81%)

取引時間後: 8:59AM

Atea Pharmaceuticals Inc (AVIR) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

4.99

( 1.63% )

買値

4.62

売値

5.10

出来高

306,558

平均取引量 (3 か月)

US$ 330,433

財務取引量

US$ 1,506,919

4.75 日の範囲 4.995

2.78 52 週間の範囲 6.45

時価総額

企業価値

129.558M

前日終値

4.91

始値

4.96

時刻

最終取引時間

VWAP

4.9156

歳入

-

純利益

-169.52M

発行済株式数

80,027,099

浮動株比率 (%)

75.04%

機関投資家保有比率 (%)

77.14%

配当利回り

PER

-2.27

株価売上高倍率 (PSR)

-

1 株当たり利益 (EPS)

-2.12

ベータ

0.32

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhib... Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. 詳細を表示

セクター

Health Care

業界

-

ウェブサイト

ateapharma.com

本社

Boston, United States

設立

2026

Atea Pharmaceuticals Inc is listed in the Health Care sector of the ナスダック市場 with ticker AVIR. The last closing price for Atea Pharmaceuticals was US$4.91. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of US$ 2.78 to US$ 6.45.

Atea Pharmaceuticals currently has 80,027,099 shares in issue. The market capitalisation of Atea Pharmaceuticals is US$399.34 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.27.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.05	1.01214574899	4.94	5.03	4.6503	382215	4.85832185	CS
4	0.63	14.4495412844	4.36	5.035	4.225	401165	4.58984233	CS
12	-0.79	-13.6678200692	5.78	5.83	4.04	339129	4.74695714	CS
26	1.56	45.4810495627	3.43	6.45	3.34	439931	4.88067455	CS
52	1.24	33.0666666667	3.75	6.45	2.78	406690	4.12794227	CS
156	1.29	34.8648648649	3.7	6.45	2.3	364856	3.65355394	CS
260	-17.99	-78.2854656223	22.98	46.9099	2.3	733103	10.66106748	CS

AVIR - Frequently Asked Questions (FAQ)

What is the current Atea Pharmaceuticals Inc share price?

The current share price of Atea Pharmaceuticals Inc is US$ 4.99

How many Atea Pharmaceuticals Inc shares are in issue?

Atea Pharmaceuticals Inc has 80,027,099 shares in issue

What is the market cap of Atea Pharmaceuticals Inc?

The market capitalisation of Atea Pharmaceuticals Inc is USD 399.34M

What is the 1 year trading range for Atea Pharmaceuticals Inc share price?

Atea Pharmaceuticals Inc has traded in the range of US$ 2.78 to US$ 6.45 during the past year

What is the PE ratio of Atea Pharmaceuticals Inc?

The price to earnings ratio of Atea Pharmaceuticals Inc is -2.27

What is the registered address of Atea Pharmaceuticals Inc?

The registered address for Atea Pharmaceuticals Inc is 225 Franklin Street, Boston, Massachusetts, 02110

What is the Atea Pharmaceuticals Inc website address?

The website address for Atea Pharmaceuticals Inc is ateapharma.com

Monksdream

Monksdream 1年前

DewDiligence

DewDiligence 2年前

AVIR phase-3 COVID trial fails—stock rises:

https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)…today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. This trial was a longshot insofar as Bemnifosbuvir is a repurposed HCV drug rather than something designed specifically for SARS-CoV-2. Moreover, the phase-2 trial for Bemnifosbuvir in COVID was unsuccessful, but AVIR plowed ahead anyhow.

I presume the share price is up slightly today because investors know that AVIR won’t waste more money pursuing COVID. AVIR had about $475M of net current assets as of 6/30/24.

AVIR’s CEO, Jean-Pierre Sommadossi, is continuing to pursue a treatment regimen for HCV, which is a rather extreme case of Zebra’s Law (#msg-172559198).

Monksdream

Monksdream 2年前

DewDiligence

DewDiligence 2年前

AVIR reports 2Q24 results—6/30/24 cash=$502.2M—down_from_$542M_at_3/31/24:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500091.html

CC slides:
https://ir.ateapharma.com/static-files/96ee237a-23d9-4515-8401-69794a5327e0

DewDiligence

DewDiligence 2年前

AVIR 1Q24 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

3/31/24 cash = $542M, down from $578M at 12/31/23.

Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).

Monksdream

Monksdream 2年前

DewDiligence

DewDiligence 2年前

AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…

DewDiligence

DewDiligence 2年前

AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.

DewDiligence

DewDiligence 3年前

AVIR rejects Tang buyout offer, as expected:

https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

The offer was for less than AVIR’s cash value.

DewDiligence

DewDiligence 3年前

It's not a serious offering for the reason mentioned in #msg-171974875.

mwn

Why is the sp going so far below the offering?

DewDiligence

DewDiligence 3年前

Paullee

Paullee 3年前

Did you not notice that a CVR of 80% is included in the package?

DewDiligence

DewDiligence 3年前

In other words, AVIR could do better than $5.75/sh by simply liquidating.

DewDiligence

DewDiligence 3年前

AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.

DewDiligence

DewDiligence 3年前

Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .

Awl416

DewDiligence

DewDiligence 3年前

AVIR 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html

DewDiligence

DewDiligence 3年前

AVIR 1Q23 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

3/31/23 cash = $621M.

V63

So AVIR beat its earnings, and now it might bump up a little tomorrow.

DewDiligence

DewDiligence 3年前

AVIR reports final data from phase-2 COVID trial:

https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html

DewDiligence

DewDiligence 3年前

AVIR 4Q22 CC transcript:

https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html

DewDiligence

DewDiligence 3年前

AVIR 4Q22 results—12/31/22 cash=$647M:

https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.

DewDiligence

DewDiligence 3年前

AVIR JPM webcast slides:

https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa

DewDiligence

DewDiligence 4年前

AVIR 2023 newsflow:

https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html

DewDiligence

DewDiligence 4年前

AVIR 3Q22 results—9/30/22 cash=$665M:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).

DewDiligence

DewDiligence 4年前

AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html

DewDiligence

DewDiligence 4年前

AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

1Q22 PR:
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

1Q22 CC slides:
https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562

DewDiligence

DewDiligence 5年前

LOL re AVIR’s attempt to be relevant:

https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html

Jake L

AVIR - Friday Rundown, Monday Expectations

Wallst_junkie

Wallst_junkie 5年前

Watching for a uptrend

dealerschool2006

dealerschool2006 5年前

GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...

crudeoil24

crudeoil24 5年前

Wow! That's why you don't hold these Pharma overnight.

AVIR

TheFinalCD

TheFinalCD 5年前

wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR

DewDiligence

DewDiligence 5年前

Why AVIR's AT-527 program is no-go: #msg-166425975.

XWAVXALMIMAN

XWAVXALMIMAN 5年前

David v Goliath

Interesting article - check out RDHL

https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html

Chess Master

Chess Master 5年前

ecommceo

ecommceo 5年前

Way over sold here.

Planopenny

Planopenny 5年前

Out at $16, easy $$$

Docstemcell2020

Docstemcell2020 5年前

Let's go Brandon! FJB :)

DewDiligence

DewDiligence 5年前

AVIR CC slides (largely BS, IMO):

https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6

Planopenny

Planopenny 5年前

rosemountbomber

rosemountbomber 5年前

Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28

rosemountbomber

rosemountbomber 5年前

DewDiligence

DewDiligence 5年前

The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597

rosemountbomber

rosemountbomber 5年前

So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.

Whalatane

Whalatane 5年前

AVIR presentation tomorrow Oct 5th

https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

Kiwi

crudeoil24

crudeoil24 5年前

You bet! > AVIR up 45% @ 50.05

Whalatane

Whalatane 5年前

Thx for the updates

Kiwi

crudeoil24

crudeoil24 5年前

AVIR up 45% @ 50.05 > premarket.

Atea Pharmaceuticals

Wrst Fxd Cpn Atcl Nts Lk...

Anaconda Share Cls Lvl P...

Evolve NASDAQ Techology

Envipco Holding Nv

Beam Therapeutics

UBS Core BBG US Liquid C...

Vontobel Financial Produ...

Cognition Therapeutics

Celulose Beira Industria...

Ci High Yield Bond Corpo...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。